What's new for 'JKB_daily1' in PubMed

This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.

Sender's message: Sepsis or genomics or altitude: JKB_daily1

Sent on Thursday, 2010 Mar 18
Search (sepsis[MeSH Terms] OR septic shock[MeSH Terms] OR altitude[MeSH Terms] OR genomics[MeSH Terms] OR genetics[MeSH Terms] OR retrotransposons[MeSH Terms] OR macrophage[MeSH Terms]) AND ("2009/8/8"[Publication Date] : "3000"[Publication Date]) AND (("Science"[Journal] OR "Nature"[Journal] OR "The New England journal of medicine"[Journal] OR "Lancet"[Journal] OR "Nature genetics"[Journal] OR "Nature medicine"[Journal]) OR (Hume DA[Author] OR Baillie JK[Author] OR Faulkner, Geoffrey J[Author]))
Click here to view complete results in PubMed. (Results may change over time.)
To unsubscribe from these e-mail updates click here.

PubMed Results

Items 1 - 2 of 2

1.	N Engl J Med. 2010 Mar 11;362(10):942-3. Toward a personalized treatment of Hodgkin's disease. DeVita VT Jr, Costa J. Comment on: N Engl J Med. 2010 Mar 11;362(10):875-85.
	PMID: 20220189 [PubMed - indexed for MEDLINE]
	Related articles
	Publication Types: Comment Editorial MeSH Terms: Antigens, CD/analysis* Antigens, Differentiation, Myelomonocytic/analysis* Disease-Free Survival Gene Expression Profiling Hodgkin Disease/genetics* Hodgkin Disease/therapy Humans Macrophages*/immunology Prognosis Reed-Sternberg Cells/pathology Substances: Antigens, CD Antigens, Differentiation, Myelomonocytic CD68 antigen, human

2.	N Engl J Med. 2010 Mar 11;362(10):875-85. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada. Comment in: N Engl J Med. 2010 Mar 11;362(10):942-3. BACKGROUND: Despite advances in treatments for Hodgkin's lymphoma, about 20% of patients still die from progressive disease. Current prognostic models predict the outcome of treatment with imperfect accuracy, and clinically relevant biomarkers have not been established to improve on the International Prognostic Score. METHODS: Using gene-expression profiling, we analyzed 130 frozen samples obtained from patients with classic Hodgkin's lymphoma during diagnostic lymph-node biopsy to determine which cellular signatures were correlated with treatment outcome. We confirmed our findings in an independent cohort of 166 patients, using immunohistochemical analysis. RESULTS: Gene-expression profiling identified a gene signature of tumor-associated macrophages that was significantly associated with primary treatment failure (P=0.02). In an independent cohort of patients, we found that an increased number of CD68+ macrophages was correlated with a shortened progression-free survival (P=0.03) and with an increased likelihood of relapse after autologous hematopoietic stem-cell transplantation (P=0.008), resulting in shortened disease-specific survival (P=0.003). In multivariate analysis, this adverse prognostic factor outperformed the International Prognostic Score for disease-specific survival (P=0.003 vs. P=0.03). The absence of an elevated number of CD68+ cells in patients with limited-stage disease defined a subgroup of patients with a long-term disease-specific survival of 100% with the use of current treatment strategies. CONCLUSIONS: An increased number of tumor-associated macrophages was strongly associated with shortened survival in patients with classic Hodgkin's lymphoma and provides a new biomarker for risk stratification. 2010 Massachusetts Medical Society
	PMID: 20220182 [PubMed - indexed for MEDLINE]
	Related articles
	Publication Types: Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't MeSH Terms: Adolescent Adult Aged Aged, 80 and over Analysis of Variance Antigens, CD/analysis* Antigens, Differentiation, Myelomonocytic/analysis* Child Disease-Free Survival Female Gene Expression Gene Expression Profiling* Gene Expression Regulation, Neoplastic Hodgkin Disease/genetics* Hodgkin Disease/mortality Hodgkin Disease/pathology Humans Immunohistochemistry Kaplan-Meiers Estimate Lymph Nodes/pathology* Macrophages*/immunology Male Middle Aged Neoplasm Staging Prognosis RNA, Neoplasm/analysis Reed-Sternberg Cells/pathology Survival Rate Treatment Failure Tumor Markers, Biological/analysis Tumor Markers, Biological/genetics Young Adult Substances: Antigens, CD Antigens, Differentiation, Myelomonocytic CD68 antigen, human RNA, Neoplasm Tumor Markers, Biological Grant Support: 178536/Canadian Institutes of Health Research/Canada U01-CA 114778/CA/NCI NIH HHS/United States U01-CA114778-01/CA/NCI NIH HHS/United States